Source: Annual Congress 2013 –Ceremony for ERS Award for Rare Pulmonary Disease (financially supported by GlaxoSmithKline) followed by Symposium: Autoimmunity and lung diseases in humans



Rating:

Share or cite this content

Citations should be made in the following way:
S. Gibbs (Manchester, United Kingdom). Amyloid-and nonamyloid-deposition disease in the lung: novel manifestations. Annual Congress 2013 –Ceremony for ERS Award for Rare Pulmonary Disease (financially supported by GlaxoSmithKline) followed by Symposium: Autoimmunity and lung diseases in humans

Member's Comments

No comment yet.

Related content which might interest you: COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011 Clues beyond the lung: an unusual diagnosis in an infant with chronic lung disease Source: Breathe, 16 (1) 190319; 10.1183/20734735.0319-2019 Year: 2020 Unclassifiable interstitial lung disease: a distinct entity with heterogeneous progression Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018 Senotherapies for chronic lung disease Source: ERS Lung Science Conference 2020 Year: 2020 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Siphonage lung disease Source: Virtual Congress 2020 – Respiratory critical care Year: 2020 Pattern and impact of rheumatology referral in patients with ILD and autoimmune features Source: International Congress 2016 – Connective tissue disorders Year: 2016 HR-CT of fibrosing lung disease: problems and variants Source: International Congress 2014 – PG02 Current clinical problems in pulmonology Year: 2014 Eosinophilic lung disease: clinical features of 25 patients Source: Eur Respir J 2006; 28: Suppl. 50, 237s Year: 2006 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Combined emphysema & interstitial pulmonary disease. A new disease entity? Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 Severe pulmonary hypertension in lung disease: phenotypes and response to treatment Source: Eur Respir J 2015; 46: 1378-1389 Year: 2015 Interstitial lung disease: new challenges and evolving phenotypes Source: Eur Respir Rev 2009; 19: 91-93 Year: 2010 The clinical spectrum and pathogenesis of pulmonary manifestations in connective tissue diseases Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=1 Year: 2005 Aspergillus-related lung disease in people with cystic fibrosis: can imaging help us to diagnose disease? Source: Eur Respir Rev, 30 (162) 210103; 10.1183/16000617.0103-2021 Year: 2021 Immunodeficiencies in adulthood: lung disease manifestations and treatment options Source: International Congress 2019 – PG6 Immunodeficiencies in lung diseases Year: 2019 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 Systemic effects in patients with chronic obstructive pulmonary disease: a role of disease duration and disease severity Source: Annual Congress 2009 - Prognosis and comorbidities in COPD Year: 2009 Clinical analysis of lung manifestation in Sjögren's syndrome Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018